E	SEP 1 4 20	スロンロン	
	4 2001		Ì

Please type a plus sign (+) inside his dox Under the Paper and Reduction Act of 150, no		U equired to re	S. Patent and Trademark	PTO/SB/21 (08-00) I for use through 10/31/2002. OMB 0651-0031 Office: U.S. DEPARTMENT OF COMMERCE nation unless it displays a valid TMB control number.	CEN			
TRANSMITTAL FORM  (to be used for all correspondence after initial filing)			ation Number	09/580,015	Z			
			Date →	May 26, 2000	<u>क</u>			
			lamed Inventor	Schenk, Dale B.	772			
			Art Unit	1641	8			
		Exami	ner Name	Unassigned				
Total Number of Pages in This Submission 12		Attorn	ey Docket Number	15270J-004750US	J			
ENCLOSURES (check all that apply)								
Fee Transmittal Form (1 page, filed in duplicate)				After Allowance Communication to Group				
Fee Attached Drawin		g(s)		Appeal Communication to Board of Appeals and Interferences				
Amendment / Response	Amendment / Response			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
		on Routing Slip (PTO/SB/69)		Proprietary Information				
		tion to Convert to a visional Application		Status Letter				
		er of Attorney, Revocation ge of Correspondence Address		Other Enclosure(s) (please identify below):				
Express Abandonment Request	Terminal Disclaimer     Request for Refund			Supplemental Application Data Sheet (pp.) and,	3			
Supplmental Information Disclosure Statement Under 37 CFR §1.97 & §1.98 (4 pp.) w/PTO/SB0/8A & 08B (3 pp.)	CD, Number of CD(s)		CD(s)	2. Return Postcard.				
Certified Copy of Priority Document(s)			The Commissioner is a Deposit Account 20-14	authorized to charge any additional fees to 130.				
Response to Missing Parts/ Incomplete Application								
Response to Missing Parts under 37 CFR 1.52 or 1.53								
			ANT, ATTORNEY, O	R AGENT	_			
and	and Rosemarie I. Celli Reg No. 42,397							
	Polemane 2. all							
	September 7, 2001							
	CE	RTIFIC	ATE OF MAILING		$\bar{\Delta}$			
I hereby certify that this correspondence is class mail in an envelope addressed to:	s being depo	sited wit	n the United States Post er for Patents, Washingt	al Service with sufficient postage as first on, D.C. 20231 on this date:				

September 7, 2001 Wanda Alleje

Date

September 7, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3168209 v1

allin

anda

Typed or printed name

Signature


ling deposited with the United I hereby certify that this correspondence States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Pate Washington, D.C. 20231

On: September 7, 2001

TOWNSEND and TOWNSEND

Wanda Alleje



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/580,015

Filed: May 26, 2000

For: PREVENTION AND TREATMENT

OF AMYLOIDOGENIC DISEASE

Examiner:

Unassigned

Art Unit:

1641

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached PTOSB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/201,430, filed November 30, 1998 (Attorney Docket No. 15270J-004720US).

The publication identified as Cite No. 144 is a grant application believed to have been submitted by Victor Raso for NIH Grant No. 1 R43 AGI 5746-01 on August 29, 1997. Applicants obtained the grant proposal under the Freedom of Information Act (FOIA). It is believed that the grant proposal would not have been accessible under FOIA before April 2, 1998, but the exact date of public accessibility is not known to applicants. The Raso NIH Grant Dale B. Schenk

Application No.: 09/580,015

Page 2

Application was previously submitted with the IDS mailed on October 30, 2000, but was not cited on the attached Form 1449.

Applicants also cite commonly owned copending applications directed to related subject matter:

```
09/204,838 filed 12/03/98;
09/201,430 filed 11/30/98;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00;
09/723,927 filed 11/28/00;
09/724,762 filed 11/28/00;
09/724,102 filed 11/28/00;
09/724,489 filed 11/28/00;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
 09/723,384 filed 11/27/00;
 09/724,495 filed 11/27/00;
 09/724,940 filed 11/28/00;
 09/724,961 filed 11/28/00;
 09/580,018 filed 05/26/00;
 09/724,552 filed 11/28/00;
 09/723,544 filed 11/28/00;
 09/724,273 filed 11/28/00;
 09/724,551 filed 11/28/00;
 09/724,288 filed 11/28/00;
 09/580,019 filed 05/26/00;
  09/723,765 filed 11/28/00;
  09/724,291 filed 11/28/00;
```

Dale B. Schenk

Application No.: 09/580,015

Page 3

```
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
09/585,817 filed 06/01/00;
09/724,567 filed 11/28/00;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00;
09/724,569 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00; and,
09/579,690 filed 05/26/00.
```

Applicants further cite the following commonly owned abandoned applications directed to related subject matter:

```
60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99; and,
60/136,655 filed 05/28/99.
```

Applicants point out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

```
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and
09/724,929 filed 11/28/00.
```

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Dale B. Schenk

Application No.: 09/580,015

Page 4

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Rosemarie L. Celli Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

RLC:rnh

PA 3163105 v1